http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2544877-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_64f502f5061071aee475cbb88dfebf4f |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-321 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-314 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-335 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55561 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-117 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-117 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate | 2006-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad2a022d9ead120e0e146bc4ad60d76a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3aa98d6fd98ca5c924c66c6d7cca70ca http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_525d4e53de21ffa4375b6d0e632ca04c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a0bc3657decde0dcf46db1d904392ae6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_10eccd928fdfb1d37cbd2251612de0e8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c7dd8cfc2e290491b9c4b6263425105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9a460431716b7a2cebf71f4d967683f |
| publicationDate | 2015-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2544877-T3 |
| titleOfInvention | Immune Regulatory Oligonucleotide Compounds (IROs) to Modulate the Toll-Like Receptor-Based Immune Response |
| abstract | A TLR antagonist comprising an immuno regulatory oligonucleotide compound (IRO) that is an antagonist for one or more TLRs having the structure in which: CG is an oligonucleotide residue that is CpG, C * pG, C * pG * or CpG *, where C is cytosine, C * is a pyrimidine nucleotide derivative which is a pyrimidine nucleotide having a non-cytosine, thymine, or uracil base and / or a sugar that is not ribose or 2'- deoxyribose and may be present in the nucleus of an oligonucleotide, G is guanosine, and G * is a purine nucleotide derivative that is a purine nucleotide that has a base that is not guanine or adenine and / or a sugar that is not ribose or 2'-deoxyribose and can be present in the nucleus of an oligonucleotide; N1-N3, at each occurrence, is independently i) a nucleotide, ii) a nucleotide derivative that is a purine or pyrimidine nucleotide that has a base that is not guanine, cytosine, adenine, thymine, or uracil and / or a sugar which is not ribose or 2'-deoxyribose and may be present in the nucleus of an oligonucleotide, or iii) a non-nucleotide linkage, provided that at least one of N1-N3 is a nucleotide derivative or non-nucleotide linkage that suppresses activity from the rest of the oligonucleotide; N1-N3, at each occurrence, is independently i) a nucleotide, or ii) a nucleotide derivative that is a purine or pyrimidine nucleotide that has a base that is not guanine, cytosine, adenine, thymine, or uracil and / or a sugar that is not ribose or 2'-deoxyribose and may be present in the nucleus of an oligonucleotide; Nm and Nm, at each occurrence, is independently a nucleotide, derived from a nucleotide that is a purine or pyrimidine nucleotide that has a base that is not guanine, cytosine, adenine, thymine, or uracil and / or a sugar that is not ribose or 2'-deoxyribose and can be present in the nucleus of an oligonucleotide, or non-nucleotide linkage; and further provided that the compound contains less than 3 consecutive guanosine nucleotides; wherein the oligonucleotide moiety would be immunostimulatory were it not for the nucleotide derivative or non-nucleotide junction that suppresses the activity of the oligonucleotide moiety; where m is a number from 0 to about 30; wherein the immuno regulatory oligonucleotide compound is not an antisense oligonucleotide; for use in the therapeutic treatment or prevention of a TLR-mediated disease in a mammal, wherein the disease is cancer, an autoimmune disorder, inflammation of the airways, inflammatory disorders, infectious disease, skin disorders, allergy, asthma, or a disease caused by a pathogen. |
| priorityDate | 2005-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 363.